FDA Commissioner Dr. Andrew von Eschenbach said his agency still is willing to consider new Cox-2 pain drugs despite an advisory panel's rejection of Merck's Arcoxia. "We'd be open to any new products coming forward, including Cox-2 inhibitors," he said in an interview. Novartis AG is awaiting an FDA decision on its new COX-2 drug Prexige.

Full Story:

Related Summaries